8-K: Viking Therapeutics Announces Positive Q3 2024 Results and Clinical Pipeline Advancements

Viking Therapeutics reported positive financial results for the third quarter of 2024, along with significant progress in its clinical programs, including obesity and NASH/MASH treatments.

Summary

• Viking Therapeutics announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update.
• The company reported a net loss of $24.9 million, or $0.22 per share, for the quarter, compared to a net loss of $22.5 million, or $0.23 per share, in the same period of 2023.
• Research and development expenses increased to $22.8 million for the quarter, up from $18.4 million in 2023, due to increased manufacturing, stock-based compensation, and regulatory services.
• General and administrative expenses also rose to $13.8 million, compared to $8.9 million in 2023, primarily due to increased stock-based compensation and legal services.
• Viking's cash position is strong, with $930 million in cash and equivalents as of September 30, 2024, compared to $362 million at the end of 2023.
• The company is advancing multiple clinical programs, including VK2735 for obesity, VK2809 for NASH/MASH, and VK0214 for X-ALD.
• An End-of-Phase 2 meeting with the FDA for subcutaneous VK2735 is planned for the fourth quarter of 2024.
• A Phase 2 study of oral VK2735 in obesity is expected to begin in the fourth quarter of 2024.
• Results from the Phase 2b VOYAGE study of VK2809 in NASH/MASH with fibrosis were selected for oral presentation at the AASLD meeting.
• Positive Phase 1b results from the VK0214 study in X-ALD demonstrated safety, tolerability, and reductions in very long-chain fatty acids and plasma lipids.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong clinical results, a robust cash position, and clear plans for future development. The company is making significant progress in multiple therapeutic areas, which is encouraging for investors.

Positives

• Viking has a substantial cash reserve of $930 million, providing financial stability for ongoing research and development.
• The company's VK2735 program for obesity has shown promising results in both subcutaneous and oral formulations.
• The VOYAGE study of VK2809 for NASH/MASH demonstrated significant improvements in liver health, including NASH resolution and fibrosis reduction.
• VK0214 for X-ALD showed positive results in a Phase 1b study, with significant reductions in key disease markers.
• The company's dual amylin and calcitonin receptor agonist program has shown encouraging preclinical results for obesity treatment.
• Multiple upcoming scientific presentations and investor events are scheduled, increasing visibility for the company.

Negatives

• The company reported a net loss of $24.9 million for the third quarter of 2024.
• Research and development expenses increased to $22.8 million for the quarter, indicating higher operational costs.
• General and administrative expenses also increased to $13.8 million for the quarter, contributing to the overall loss.

Risks

• Clinical trial results may not always be replicated in larger studies.
• Regulatory approvals for drug candidates are not guaranteed.
• The company's financial performance is subject to fluctuations in research and development costs.
• There are risks associated with the success, cost, and timing of product development activities and clinical trials.
• The company is subject to risks regarding regulatory requirements.

Future Outlook

Viking expects to achieve multiple important milestones with its clinical programs, supported by its strong cash position. The company plans to advance VK2735 into a Phase 3 program for obesity and initiate a Phase 2 trial of oral VK2735 in Q4 2024. They also plan to file an IND application for their amylin agonist program in 2025.

Management Comments

• Brian Lian, Ph.D., chief executive officer of Viking, stated that the first three quarters of 2024 have been a productive period for Viking, with positive results announced from four different clinical trials and promising initial findings reported from a new preclinical program.
• Management believes they have the financial resources to achieve multiple important milestones with their clinical programs.

Industry Context

This announcement is significant in the context of the competitive landscape for obesity and NASH/MASH treatments. Viking's positive results position them as a strong contender in these therapeutic areas, particularly with their dual-agonist approach for obesity and liver-selective thyroid hormone receptor agonist for NASH/MASH. The company's focus on both subcutaneous and oral formulations for VK2735 also addresses different patient preferences.

Comparison to Industry Standards

• Viking's VK2735 weight loss results, with up to 14.7% reduction in body weight, are competitive with other GLP-1 based therapies such as those from Eli Lilly (Tirzepatide) and Novo Nordisk (Semaglutide).
• The NASH/MASH resolution rates of 63% to 75% achieved with VK2809 are impressive compared to other NASH treatments in development, such as those from Madrigal Pharmaceuticals (Resmetirom).
• The safety and tolerability profile of VK2809 is also notable, with minimal GI side effects, which is a common issue with other NASH treatments.
• The reduction in very long-chain fatty acids and plasma lipids with VK0214 in X-ALD patients is a significant finding, as there are currently no approved pharmacologic treatments for this rare disease.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results and financial position.
• Employees may be motivated by the company's progress and future prospects.
• Patients with obesity, NASH/MASH, and X-ALD may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Viking plans to hold an End-of-Phase 2 meeting with the FDA for subcutaneous VK2735 in Q4 2024.
• The company expects to initiate a Phase 2 study of oral VK2735 in obesity in Q4 2024.
• Viking will present results from the VOYAGE study of VK2809 at The Liver Meeting in November 2024.
• The company will continue to evaluate the complete data set for VK0214 and consider next steps for this program.
• Viking expects to file an IND application for its dual amylin and calcitonin receptor agonist program in 2025.

Key Dates

Keywords

Viking Therapeutics, VK2735, VK2809, VK0214, Obesity, NASH, MASH, X-ALD, Clinical Trials, Metabolic Disorders, GLP-1, GIP, Thyroid Hormone Receptor Agonist, Amylin Agonist, Biopharmaceutical